6/25/2019  5:36:15 PM Chg. -0.020 Volume Bid6/25/2019 Ask6/25/2019 Market Capitalization Dividend Y. P/E Ratio
2.600EUR -0.76% 252
Turnover: 645.600
-Bid Size: - -Ask Size: - 400.39 mill.EUR 0.00% -

Business description

The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.
 

Management board & Supervisory board

CEO
Dr. Jason Loveridge
Management board
Dr. med. Frank Hermann, Dr. med. Susanne Danhauser-Riedl
Supervisory board
Dr. Clemens Doppler, Joerg von Petrikowsky, Dr. Irina Antonijevic, Dr. Manfred Rüdiger, Helmut Jeggle, Prof. Dr. Helga Rübsamen-Schaeff
 

Company data

Name: 4SC AG
Address: Fraunhoferstraße 22,D-82152 Planegg-Martinsried
Phone: +49-89-700763-0
Fax: +49-89-700763-29
E-mail: -
Internet: www.4sc.de
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 31.10%
IPO date: 12/15/2005

Investor relations

Name: Dr. Anna Niedl
IR phone: +49-89-700763-73
IR-Fax: -
IR e-mail: anna.niedl@4sc.com

Company calendar

CW 32 | 8/8/2019 Interim Report 2nd Quarter/6 Months
CW 42 | 10/17/2019 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Santo Holding
 
37.50%
Freefloat
 
31.10%
ATS Beteiligungsverwaltung GmbH
 
20.90%
First Capital Partner GmbH
 
6.00%
Wellington Partners
 
4.50%